On Monday, CIGNA Corporation (NYSE:CI)‘s shares declined -0.66% to $130.27.
Yesterday, Whether or not you were a premature baby, or you had a premature baby, everyone is influenceed by preterm birth. That’s the message behind “It’s Personal,” the theme of Cigna’s (CI) 21st national March of Dimes campaign.
In 21 years as a national sponsor of March of Dimes and their signature March for Babies events, Cigna employees and the Cigna Foundation have given $30 million to assist March of Dimes give babies a healthier start.
“March for Babies is a very personal experience for our employees – many tell me they get even more out of the experience than the energy they put into it,” said David Cordani, Cigna’s president and CEO. “Together with the March of Dimes, Cigna is proud to support improving the health of the next generation.”
Cigna employees are actively engaged in the March of Dimes March for Babies events in their communities nationwide. Participants will see Team Cigna showing their commitment together at many marches, and at many of the 10 Run for Babies locations where Cigna has offices.
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The company’s Commercial segment offers insured and self-insured customers medical, dental, behavioral health, and vision, in addition to prescription drug benefit plans, health advocacy programs, and other products and services. Its Government segment offers Medicare Advantage plans to seniors in 16 states and the District of Columbia, Medicare Part D plans in 50 states and the District of Columbia, and Medicaid plans.
Petroquest Energy Inc (NYSE:PQ)’s shares dropped -1.55% to $2.54, during the last trading session on Monday.
Formerly on March 30, Petroquest Energy Inc (PQ), declared that the Company’s bank group has accomplished its semi-annual re-determination of its borrowing base under its credit facility. As a result, the Company’s $220 million borrowing base has been revised to $190 million, subject to the aggregate commitments of the bank group, which the Company elected to remain unchanged at $170 million. In addition, the Company’s minimum ratio of merged current assets to merged current liabilities has been amended to the following: 0.75 to 1.0 as the last day of the fiscal quarters ending March 31, 2015 and June 30, 2015, and 1.0 to 1.0 as the last day of any fiscal quarter ending thereafter.
The Company is presently in compliance with the financial covenants under the credit facility. The Company has requested an interim re-determination of the borrowing base which is planned to occur by July 1, 2015 and will be based upon the valuation of the reserves attributable to the Company’s oil and gas properties as of July 1, 2015.
PetroQuest Energy, Inc. operates as an independent oil and gas company. The company is involved in the acquisition, exploration, development, and operation of oil and gas properties in Oklahoma and Texas, in addition to onshore and in the shallow waters offshore the Gulf Coast Basin.
At the end of Monday’s trade, BioMarin Pharmaceutical Inc (NASDAQ:BMRN)‘s shares dipped -0.65% to $120.13.
On April 14, BioMarin Pharmaceutical Inc (BMRN), declared that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 30, at 4:30 p.m. ET to talk about first quarter 2015 financial results and provide a general business update.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
Perrigo Company plc Ordinary Shares (NYSE:PRGO), ended its Monday’s trading session with -0.45% loss, and closed at $198.08.
Yesterday, Perrigo Animal Health is a division of Perrigo Company plc (NYSE: PRGO; TASE), a leading global manufacturer of over-the-counter healthcare products. Comprised of Sergeant’s, SENTRY® and PetArmor® brands, Perrigo Animal Health brings quality, affordable flea and tick treatments, health and well-being solutions, and consumables for dogs and cats to grocery, mass, dollar, drug, club and pet specialty retailers.
For the second year in a row, Perrigo Animal Health, the manufacturer of PetArmor® brand products, is encouraging Americans to show their appreciation for these K-9 heroes and has declared the week of April 20, 2015, as “National Thank a Police Dog Week.” People can send thanks to a K-9 officer and his human counterpart by visiting petarmor.com/thankapolicedog until April 28 and clicking on a photo of their choice.
PetArmor products assist improve the overall health of pets across the U.S. by providing vet-quality products that are both affordable and accessible. Dedicated to its mission of pet protection, Perrigo Animal Health is assisting to ensure more K-9 officers are protected while in the line of duty. More often than not, law enforcement agencies do not have the budget to provide bullet- and stab-protective vests for their K-9 officers because each vest costs about $1,000. As a result, police dogs are left unprotected while fighting crime.
Perrigo Animal Health began its partnership with Vested Interest in K9s, Inc. — a nonprofit organization that provides bullet- and stab-protective vests to police organizations nationwide — in 2013 and has since vested 50 dogs in Florida, Maryland, Michigan, Nevada, Tennessee and Texas. In 2015, the brand is donating an additional 25 vests that will benefit K-9 officers at police departments nationwide.
Perrigo Company plc, through its auxiliaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, in addition to in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
